Mirabegron

Mirabgeorn, Myrbetriq

beta3-Adrenergic Agonist

NADAC/unit $2.2107

No Shortage Tier 1: 46.8% 6 Manufacturers 13 ANDAs

Mirabegron extended-release tablets are beta-3 adrenergic agonist indicated for the treatment of: Overactive bladder (OAB) in adult patients with symptoms of urge urinary incontinence, urgency, and....

vs. brand Mirabgeorn: Generic saves up to 78% per unit

Covered Lives

Generic Manufacturers

ALKEM LABORATORIES LTDASCENT PHARMACEUTICALS INCASTELLAS PHARMA GLOBAL DEVELOPMENT INCLUPIN LTDMSN LABORATORIES PRIVATE LTDQILU PHARMACEUTICAL CO LTDZYDUS PHARMACEUTICALS USA INC

Explore in the Ecosystem

rxsaver.aiCompare prices for Mirabegron drfinder.aiFind doctors who prescribe Mirabegron rxbenefits.aiEmployer cost impact analysis clinicalrx.aiClinical profile: Mirabegron

Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.